Avatar-based Therapy for Female Orgasmic Disorder

December 29, 2023 updated by: Ariana Vila, Universidad Rey Juan Carlos

An Avatar-based Intervention in Second Life for Female Orgasmic Disorder: A Randomized Control Trial

A randomized controlled trial was conducted for testing the efficacy of a novel avatar-based intervention (IG), that was compared with a control group (CG) for women with female orgasmic disorder (FOD). Participants were 31 women who were randomly assigned to the intervention or the control conditions. Intervention was based on the cognitive behavioral therapy approach (treatment with the most empirical evidence) and previous literature about FOD. It consisted of 12 weekly online individual sessions and aimed at improving the FOD diagnosis, sexual variables, and variables that are known to affect orgasm consecution. Control group was based on minimum therapeutic contact. Changes over time in the assessed variables were analyzed using linear mixed models, considering treatment group, measurement time point, and group-by-time interactions as fixed effects. Effect sizes were computed (Cohen's d; number needed to treat - NNT; reliable change index - RCI).

Study Overview

Study Type

Interventional

Enrollment (Actual)

31

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Madrid
      • Alcorcon, Madrid, Spain, 28922
        • Rey Juan Carlos University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Present the characteristics to diagnose female orgasm disorder after a clinic assessment (considering natural characteristics of the women's sexual response cycle (Conn & Hodges, 2022) based on the DSM-5 criteria.
  • Provide a medical check to prove the absence of physical factors that may be the cause of the orgasm dysfunction, as this is the first part to diagnose FOD.
  • Be at least 18 years old (adult).
  • Have access to a computer with the characteristics to run Second Life and internet connection.

Exclusion Criteria:

  • Present a diagnosis of a physical condition that may be the cause of the orgasm dysfunction (e.g., genital lesions, systemic and hormonal factors, vulvovaginal atrophy).
  • Presence of other psychological pathology (e.g., depression, trauma) that may be the cause of the orgasm dysfunction.
  • Have alcohol dependence (i.e., evaluated during the clinical assessment, according to the diagnostic criteria from the DSM-5, to determine if the individual meets the criteria for an alcohol use disorder diagnosis).
  • Drug use, including medication that is known to cause sexual difficulties (e.g., selective serotonin reuptake inhibitors (SSRIs), that are a particularly common drug cause of sexual dysfunction.
  • Have participated in a previous psychological intervention in the last year.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Avatar-based Intervention Group
Treatment was based on the CBT approach and previous literature about FOD. It consisted of 12 weekly online individual sessions, which were administered once a week (total duration = 3 months) and lasted about 60 minutes each.

Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective.

It was delivered via a metaverse: Second Life.

Active Comparator: Minimal support control group
It consisted in individual informative talks, during which they were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.
Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure). Participants received three individual sessions once a month, and had a duration of one hour.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sexual satisfaction assessed by the Golombok Rust Inventory of Sexual Satisfaction
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up

Sexual satisfaction is the feeling of pleasure that one has when the sexual desire has been fulfilled.

The Golombok Rust Inventory of Sexual Satisfaction has minimum-maximum values of 0-112; higher scores mean a worse outcome. The cut-off for determining significant levels of Sexual Satisfaction is 60 (scores equal to or above 60 indicate the existence of a sexual problem).

From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
Sexual functionassessed by the Female Sexual Function Index
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
Sexual function refers to the capacity of having a satisfactory sexual life. The Female Sexual Function Index has minimum-maximum values of 19-95; higher scores mean a better outcome. The cut-off for determining significant levels of this variable is 55 (scores equal to or below 55 indicate poor Sexual Function).
From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
Initiative and Sexual Communication assessed by the Female Sexual Function Questionnaire
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up

Initiative and Sexual Communication is the proactive and consensual expression of one's sexual desires, interests, and intentions within the context of a sexual relationship or encounter.

The Female Sexual Function Questionnaire has minimum-maximum values of 14-70; higher scores mean a better outcome. The cut-off for determining significantly low levels of this variable are scores equal to or lower than 25.

From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sexual self-esteem assessed by the Rosenberg Self-Esteem Scale
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
Self-esteem related to sexuality; may influence on the consecution of orgasms. The Rosenberg Self-Esteem Scale has minimum-maximum values of 10-40; higher scores mean a better outcome. The cut-off for clinical low self-esteem is a score equal to or lower than 25.
From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
Sex-guilt assessed by the Brief Mosher Sex-Guilt Scale
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
Sex-guilt related to sexuality; may influence on the consecution of orgasms. The Brief Mosher Sex-Guilt Scale has minimum-maximum values of 10-60; higher scores mean a worse outcome (higher scores indicate higher levels of guilt).
From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
Sexual anxiety by the Sexual Anxiety scale of the Expanded Sexual Arousability Inventory
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up

Sexual anxiety related to sexualiaty; may influence on the consecution of orgasms.

TheSexual Anxiety scale of the Expanded Sexual Arousability Inventory has minimum-maximum values of 0-168; higher scores mean a worse outcome (higher scores indicate higher levels of sexual anxiety).

From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2022

Primary Completion (Actual)

June 1, 2023

Study Completion (Actual)

June 1, 2023

Study Registration Dates

First Submitted

December 5, 2023

First Submitted That Met QC Criteria

December 29, 2023

First Posted (Estimated)

January 1, 2024

Study Record Updates

Last Update Posted (Estimated)

January 1, 2024

Last Update Submitted That Met QC Criteria

December 29, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UniversidadRJC 2005202114121

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Female Orgasmic Disorder

Clinical Trials on Avatar-based intervention

Subscribe